Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis
article
OA: gold
CC0
Abstract
INTRODUCTION: Acquired hemophilia A (AHA) is a rare bleeding disease caused by autoantibodies against factor VIII (FVIII). Spontaneous bleeding symptoms usually affect the skin, musco, muscle, and internal organs, while joint hemarthrosis in AHA is an extremely rare manifestation. AHA may have an autoimmune cause and is often associated with autoimmune disease, but no demonstrable platelet impairment was found in AHA patients. We report a patient with AHA complicated with a right shoulder joint hemarthrosis and immune thrombocytopenia. The patient was treated with fresh frozen plasma (FFP) and human prothrombin complex concentrate (hPCC) to control the active bleeding. Simultaneously this patient firstly accepted cyclophosphamide combined with prednisone to eradicate the inhibitor, while the treatment effect of cyclophosphamide combined with prednisone was not satisfactory. At last, she was successfully treated through the use of an anti-CD20 monoclonal antibody. CONCLUSION: AHA is an autoimmune disease and can co-exist with immune cytopenia besides connective tissue disease (CTD). Joint hemarthrosis is not specific to congenital hemophilia and mainly related to the extent of prolonged aPTT and weight loading of joint in AHA. When the first-line therapy of cyclophosphamide combined with prednisone is not enough to eradicate the inhibitor, especially for a higher inhibitor titer, anti-CD20 monoclonal antibody could play an important role.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (19)
- doi:10.1111/1346-8138.13546 via openalex
- doi:10.1111/j.1365-3148.2006.00669.x via openalex
- doi:10.1016/s0049-3848(12)70019-1 via openalex
- doi:10.1111/j.1365-2516.2006.01342.x via openalex
- W1567240703 via openalex
- doi:10.1111/j.1365-2516.2012.02909.x via openalex
- doi:10.1055/s-0038-1650169 via openalex
- doi:10.1046/j.1365-2257.2000.00316.x via openalex
- doi:10.1111/hae.13040 via openalex
- doi:10.1177/107602960000600206 via openalex
- doi:10.1179/1607845412y.0000000057 via openalex
- W6684812046 via openalex
- doi:10.1002/14651858.cd011907 via openalex
- doi:10.1002/ajh.24777 via openalex
- doi:10.3324/haematol.2017.185330 via openalex
- doi:10.1002/14651858.cd011907.pub2 via openalex
- doi:10.1016/j.autrev.2013.08.001 via openalex
- doi:10.1182/blood-2012-02-409185 via openalex
- doi:10.1182/blood-2006-06-029850 via openalex
Source provenance
- openalex
- last seen: 2026-05-14T06:02:11.780192+00:00
License: CC0
· commercial use OK